Florida Boards

  • Medicine

  • Nursing

  • Dentistry

  • Pharmacy

  • Optometry

  • Massage Therapy

  • Psychology

  • Chiropractic Medicine

  • Occupational Therapy

  • Osteopathic Medicine

  • Physical Therapy

  • Acupuncture

  • Athletic Training

  • Clinical Laboratory Personnel

  • Hearing Aid Specialist

  • Mental Health Professions

  • Nursing Home Administrators

  • Opticianry

  • Orthotists & Prosthetists

  • Podiatric Medicine

  • Respiratory Care

  • Speech-Language Pathology & Audiology


Dietetics and Nutrition Practice | Electrolysis | Licensed Midwifery | Physician Assistants


Certified Master Social Workers | Pain Management Clinics | Dental Laboratories | Paramedics | Emergency Medical Technicians | Radiologic Technicians | Medical Physicists | School Psychologists | Office Surgery Registration | Genetic Counseling

Important Updates Regarding the Revised Emergency Use Authorization, Direct Order, and Reporting Process for REGEN-COV Monoclonal Antibody Therapy

August 5, 2021

The United States Food and Drug Administration (FDA) revised the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together), authorizing REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. REGEN-COV is not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus – only after exposure to the virus. You can read more about the FDA’s revision here.

The federal government has developed a process for practitioners and facilities to order directly from the distributor, AmerisourceBergen (ABC). These details and resources are listed below. Facilities that may request resources may include hospitals, skilled nursing facilities, and long-term care facilities.

Process Overview

  • Facilities (based on classes of trade), are able to order REGEN-COV (Regeneron) monoclonal antibodies for their facilities.
  • Facilities will be required to:
    • Provide ABC with a board of pharmacy license or physician letter of authorization.
    • Attest to their designated class of trade and that they will administer the authorized product according to the terms of the FDA issued EUA.
    • Provide utilization data via either TeleTracking or Centers for the Disease Control and Prevention’s National Healthcare Safety Network (NHSN).
  • Facilities can order product based on established minimum amounts; subsequent orders are subject to a maximum amount based on previous orders and utilization.

Required Utilization Reporting

  • Weekly reporting on these therapeutics is required every Wednesday through the United States Department of Health and Human Services (HHS) Protect, TeleTracking, or NHSN depending on facility type.
  • Instructions are included at the bottom of the ABC order form and included here for reference.
    • To improve availability of treatments for Monoclonal Antibody (mAb) therapies for COVID-19 patients across the nation, the federal government requires entities receiving shipments of mAb treatments to provide weekly reports of mAb treatments administered and stocks on hand through one of the following reporting mechanisms:
      • For Hospitals, mAb therapeutic data reporting is included in the COVID-19 hospital data reporting as described in HHS FAQ/Guidance.
      • Skilled Nursing Facilities / Long Term Care Facilities are requested to provide data through the NHSN data system at a future date (guidance forthcoming).
      • All Additional Facilities such as Dialysis Centers, Home Health Services, Oncology, and Infusion Centers, are required to provide the requested data through the United States Health Care COVID-19 Portal.
  • First-time users will receive enrollment and reporting instructions in an e-mail from protect-noreply@hhs.gov with the subject line of 'Invitation: HHS TeleTracking COVID-19 Portal." This email provides step-by-step instructions to access the portal for the first time. If you do not receive an email in the next 48 hours, please contact TeleTracking's Technical Support at hhs-protect@teletracking.com.

Health care providers decide whether these investigational treatments are appropriate to treat COVID-19. Find facilities administering this treatment by using the National Infusion Center Locator.

Weekly Provider Conference Call Information

A conference call regarding HHS / ASPR Allocation, Distribution, and Administration of COVID-19 Therapeutics is held every Thursday, where health care providers can ask HHS questions regarding monoclonal antibodies.

Date: Thursday, August 5, 2021
Time: 2:00 - 2:30pm EST
Zoom Link: https://bit.ly/3rfRv4E

  • Meeting ID: 160 432 9034
  • Passcode: 897674


Additional Resources


Content provided by the Florida Department of Health presented herein is for informational purposes only. The Department has not screened each individual or organization that appears on this site or that is electronically linked to this site. The appearance of an individual or organization on this site is not intended as or in any manner serves as an endorsement of that individual or organization or any products or services identified on the individual’s or organization’s site. The Department disclaims any and all warranties with regard to the Website and Website information, including without limitation (A) Any implied warranties of merchantability, fitness for a particular purpose, infringement or title, (B) Any warranty of quality, functionality, operability, use or performance of the Website or Website information, (C) Any warranty of the accuracy completeness or validity of data or information communicated through the Website or included in the Website information, (D) Any warranty of the continuous availability of the Website or Website information, or that the Website or Website information will be uninterrupted or error-free, (E) Any warranty that the Website information or other files or data available for access or downloading will be free of infection, viruses, or other code manifesting harmful, contaminating, or destructive properties, or (F) Any warranties arising from course of dealing, trade usage, trade practice or otherwise. In addition, the Department does not represent or warrant that any defects in the Website or errors in the Website information will be corrected. In addition, the department does not warrant either expressly or by implication any individual, organization, product or service appearing on this site or that is electronically linked to this site. The department strongly urges all users of this site to conduct their own investigation of any individual, organization, product or service appearing on this site or that is electronically linked to this site.

Various clipart and image collections appearing on this site are used under license by the department or its web managers for this site. These images are for viewing purposes only. Any reproduction may be prohibited under federal/state copyright or trade secret laws.